AT
Avery Therapeutics, Inc.
SEC filingBiotechnology · Tucson, AZ
Amount raised$8.5Msold at filing
Total offering$15.4M$6.9M still open
Investors in the raise23count reported to the SEC
FiledSep 21, 2026first sale Aug 19, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Emile NuwaysirDirector
Jordan LancasterExecutive Officer, Director
Steven GoldmanExecutive Officer
Lawrence MehrenDirector
Executive officers, directors and promoters as listed on the Form D.